Ronald McClurg's departure as Chief Financial Officer of NEUROONE MEDICAL TECHNOLOGIES Corp was reported; the filing names no successor. As of November 6, 2026, NEUROONE MEDICAL TECHNOLOGIES Corp has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on April 30, 2026, naming 1 departure (Form 8-K, April 30, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like NEUROONE MEDICAL TECHNOLOGIES Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
NEUROONE MEDICAL TECHNOLOGIES Corp reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-04-30. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as NEUROONE MEDICAL TECHNOLOGIES Corp files it.
Also on the record for NEUROONE MEDICAL TECHNOLOGIES Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 14, 2026 | Stake report, Schedule 13G/A, by Brian Pratt | 12.5% of the class | 5%+ stakes | Source |
| April 21, 2026 | Stake report, Schedule 13G, by Brian Pratt | 7.4% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G/A, by Sio Capital Management, LLC | 4.72% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G, by Bleichroeder LP | 8.03% of the class | 5%+ stakes | Source |
| August 13, 2025 | Stake report, Schedule 13G, by Sio Capital Management, LLC | 7.07% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs NEUROONE MEDICAL TECHNOLOGIES Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on NEUROONE MEDICAL TECHNOLOGIES Corp and the records around it.
NEUROONE MEDICAL TECHNOLOGIES Corp elsewhere on the record
Companies that share a holder
- Sio Capital Management, LLC also filed stake reports on 9 other companies: Enveric Biosciences, Inc. (Nov 2026), Adagio Medical Holdings, Inc. (Jul 2026), PMV Pharmaceuticals, Inc. (Jul 2026)
- Bleichroeder LP also filed stake reports on 16 other companies: MDxHealth SA (Oct 2026), Identiv, Inc. (INVE) (Aug 2026), Cellectar Biosciences, Inc. (Aug 2026)
Watch NEUROONE MEDICAL TECHNOLOGIES Corp
Get an email when NEUROONE MEDICAL TECHNOLOGIES Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on NEUROONE MEDICAL TECHNOLOGIES Corp?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on NEUROONE MEDICAL TECHNOLOGIES Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NEUROONE MEDICAL TECHNOLOGIES Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-30 | Out | Chief Financial Officer | 8-K, 2026-04-30 |
Who leads NEUROONE MEDICAL TECHNOLOGIES Corp, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Ronald McClurg, departure reported (filed 2026-04-30). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on NEUROONE MEDICAL TECHNOLOGIES Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at NEUROONE MEDICAL TECHNOLOGIES Corp, with the record behind each one.
Find candidates like Chief Financial Officer at NEUROONE MEDICAL TECHNOLOGIES CorpEvery change, in the filing's words
Departing: Ronald McClurg, Chief Financial Officer
On April 24, 2026, Ronald McClurg notified NeuroOne Medical Technologies Corporation (the "Company") of his intention to retire as the Company's Chief Financial Officer.
- The effective date of Mr. McClurg's retirement as Chief Financial Officer will be June 30, 2026.
- Following his retirement as an officer, Mr. McClurg will remain employed by the Company as a Senior Advisor, to ensure a smooth transition of duties, until December 31, 2026 (the "Retirement Date").
- In connection with Mr. McClurg's retirement, the Board announced that Christopher Volker, the Company's Chief Operating Officer, will succeed Mr. McClurg as the Company's Chief Financial Officer effective as of July 1, 2026.
- Mr. Volker has extensive experience in the medtech industry, including senior leadership roles at Abbott, Cardiovascular Systems, Inc. ("CSI"), and St. Jude Medical.
- At CSI, he served as Vice President & General Manager of International and had direct responsibility for international P&L and commercial expansion, including sales, training & education, marketing, business development and program management.
- Prior to CSI, Mr. Volker held executive leadership roles at St. Jude Medical, including senior roles in corporate finance where he reported directly to St. Jude Medical's Chief Financial Officer.
- He began his career in healthcare and technology investment banking, where he developed expertise in financial analysis, mergers and acquisitions, strategic planning, growth equity investments and financings.
Tools for this story
Each opens in a new tab, filled in for NEUROONE MEDICAL TECHNOLOGIES Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.